Sorafenib (Bay 43-9006)

Alias: BAY 43-9006; BAY-439-006; BAY439006; BAY-439006; BAY 439006; BAY 549085; trade name: Nexavar; SFN
Cat No.:V1010 Purity: ≥98%
Sorafenib (BAY549085; BAY-549085; BAY439006; BAY-439006; Nexavar; SFN), an approved anticancer drug, is a potent and orally bioavailable multikinase inhibitor with potential anticancer activity.
Sorafenib (Bay 43-9006) Chemical Structure CAS No.: 284461-73-0
Product category: Raf
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
50mg
100mg
500mg
1g
2g
5g
10g
Other Sizes

Other Forms of Sorafenib (Bay 43-9006):

  • Sorafenib Tosylate (Bay 43-9006; Nexavar)
  • Donafenib (Sorafenib D3; Bay-43-9006 D3; CM4307)
  • Sorafenib (D4)
  • Sorafenib-13C,d3
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description
Sorafenib (BAY549085; BAY-549085; BAY439006; BAY-439006; Nexavar; SFN) an approved anticancer medication, is a potent and orally bioavailable multikinase inhibitor with potential anticancer activity (BAY549085; BAY-549085; BAY439006; BAY-439006; Nexavar; SFN). In enzymatic assays, it inhibits numerous kinases, including Raf-1, B-Raf, and VEGFR-2, with IC50 values of 6 nM, 22 nM, and 90 nM, respectively. The FDA granted sorafenib approval in 2005 to treat advanced renal cancer.
Biological Activity I Assay Protocols (From Reference)
Targets
VEGFR3 (IC50 = 20 nM); Braf (IC50 = 22 nM); Raf-1 (IC50 = 6 nM); VEGFR2 (IC50 = 90 nM); PDGFRβ (IC50 = 57 nM); BrafV599E (IC50 = 38 nM); c-Kit (IC50 = 68 nM); Flt3 (IC50 = 58 nM)
ln Vitro
Sorafenib's IC50 values of 22 nM and 38 nM, respectively, inhibit both wild-type and V599E mutant B-Raf activity. Additionally, mVEGFR2 (Flk-1) as well as mVEGFR3, mPDGFRβ, Flt3, and c-Kit are all potently inhibited by sorafenib, with respective IC50 values of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM. Sorafenib has a 580 nM IC50 and only moderately inhibits FGFR-1. Sorafenib tosylate is ineffective against the following targets: ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. In NIH 3T3 cells, sorafenib significantly reduces VEGFR2 phosphorylation with an IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with an IC50 of 20 nM. In most cell lines, sorafenib potently inhibits MEK 1/2 and ERK 1/2 phosphorylation, but not in A549 or H460 cells. It has no impact on the PKB pathway's inhibition. Sorafenib has an IC50 of 0.28 μM and 2.6 μM, respectively, and prevents HAoSMC and MDA-MB-231 cells from proliferating. [1] Sorafenib also significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner, in addition to inhibiting the RAF/MEK/ERK signaling pathway. With IC50 values of 6.3 μM and 4.5 μM, respectively, sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells and significantly induces apoptosis.[2]
ln Vivo
Sorafenib (60 mg/kg) administered orally exhibits no toxicity and broad spectrum, dose-dependent anti-tumor activity against a number of human tumor xenograft models, including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549. Sorafenib treatment significantly reduces tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29, and Colo-205 tumor xenografts, which is associated with its anti-tumor efficacy. However, it has no effect on MEK 1/2 phosphorylation or pERK 1/2 levels in HT-29 or MDA-MB-231 xenografts.[1] In SCID mice, sorafenib treatment results in a dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively. This is consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] By inhibiting NF-B mediated Mcl-1 and cIAP2 expression, sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner. In TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts, sorafenib (30–60 mg/kg) and TRAIL (5 mg/kg) showed dramatic efficacy. [3]
Enzyme Assay
Raf-1 (80 ng), wt BRAF (80 ng), or V599E BRAF (80 ng) are mixed with MEK-1 (1 μg) in the assay buffer (20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol) to test the effects of the compound on different RAF kinase isoforms. Adding 25 μL of 10 μM γ-[33P]ATP (400 Ci/mol) and incubating the mixture at 32°C for 25 minutes kickstarts the RAF kinase assay (final volume of 50 μL). By filtering phosphorylated MEK-1 onto a phosphocellulose mat, radioactivity that is not bound to the protein is removed. Phosphorylated MEK-1 is then harvested. Using a β-plate counter, filter-bound radioactivity is measured after drying by microwave heating.
Cell Assay
For 72 hours, Sorafenib tosylate is infused into cells at progressively higher concentrations. The Cell TiterGlo ATP Luminescent assay kit is used to calculate the number of cells. This assay counts the number of live cells in each well by measuring the luminescent signal, which is dependent on the amount of cellular ATP.
Animal Protocol
Mice: Female NCr-nu/nu mice are used. Mice bearing 75 to 150 mg tumors are treated orally with Sorafenib (7.5 to 60 mg/kg), administered daily for 9 days. In each model, Sorafenib produces dose-dependent tumor growth inhibition with no evidence of toxicity, as measured by increased weight loss relative to control animals or drug-related lethality. In parallel to the antitumor efficacy studies, additional groups of four mice bearing 100 to 200 mg tumors are treated orally with vehicle or Sorafenib (30 to 60 mg/kg), administered daily for 5 days, which is the shortest treatment duration producing complete tumor stasis in the treated groups.
Rats: Male albino rats weighing 100 to 120 g are used for the study. Rats are weighed and randomly split into three groups following an acclimatization period. For 8 weeks, the car is given daily to Group 1 (the healthy control group; n=10). An i.p. single dose of 200 mg/kg DENA is administered to Group 2 (the DENA group; n=15). Six weeks after receiving a DENA intravenously in Group 3 (the Sorafenib group; n=12), Sorafenib is administered orally at a dose of 10 mg/kg daily for two weeks. Rats are weighed, put to sleep with ether, killed at the conclusion of the experiment (8 weeks), and their livers are removed. Fresh liver is weighed after being dried on a clean paper towel and going through two ice-cold saline washes. The liver index is calculated using the formula liver weight (g)/final body weight (g)×100.
References

[1]. Cancer Res . 2006 Dec 15;66(24):11851-8.

[2]. Cancer Res (2004) 64 (19): 7099–7109.

[3]. Cancer Cell . 2007 Jul;12(1):66-80.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C21H16CLF3N4O3
Molecular Weight
464.82
Exact Mass
464.09
Elemental Analysis
C, 54.26; H, 3.47; Cl, 7.63; F, 12.26; N, 12.05; O, 10.33
CAS #
284461-73-0
Appearance
white solid powder
SMILES
CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
InChi Key
MLDQJTXFUGDVEO-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
Chemical Name
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
Synonyms
BAY 43-9006; BAY-439-006; BAY439006; BAY-439006; BAY 439006; BAY 549085; trade name: Nexavar; SFN
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~63 mg/mL (~135.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
5%DMSO+45%PEG400+50%H2O: 0.375mg/mL (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.1514 mL 10.7569 mL 21.5137 mL
5 mM 0.4303 mL 2.1514 mL 4.3027 mL
10 mM 0.2151 mL 1.0757 mL 2.1514 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02185560 Active
Recruiting
Drug: Sorafenib
(Nexavar, BAY43-9006)
Thyroid Carcinoma Bayer June 27, 2014
NCT00265798 Active
Recruiting
Drug: Sorafenib Tosylate Gastrointestinal Stromal Tumor National Cancer Institute
(NCI)
September 14, 2005 Phase 2
NCT01817751 Active
Recruiting
Drug: valproic acid
Drug: sildenafil citrate
Glioblastoma
Malignant Glioma
Virginia Commonwealth University April 11, 2013 Phase 2
NCT03412773 Active
Recruiting
Drug: Tislelizumab
Drug: Sorafenib
Hepatocellular Carcinoma
(HCC)
BeiGene December 28, 2017 Phase 3
NCT01840592 Active
Recruiting
Drug: Sorafenib
Drug: Doxorubicin
Hepatocellular Carcinoma Memorial Sloan Kettering Cancer
Center
April 2013 Phase 2
Biological Data
  • Sorafenib free base

    The number of nuclei breaking the internal limiting membrane (ILM). A: Controlled group; B: ROP group; C: Vehicle-treated ROP group; D: Low doses sorafenib-treated ROP group; E: Middle doses sorafenib-treated ROP group; F: High dose sorafenib-treated ROP group.

  • Sorafenib free base
  • Sorafenib free base
Contact Us